{
    "clinical_study": {
        "@rank": "36802", 
        "arm_group": {
            "arm_group_label": "Immunoglobulin Therapy"
        }, 
        "brief_summary": {
            "textblock": "Primary:\n\n        -  Demonstrate the utility of an electronic data capture (EDC) system (CareExchange\u2122)\n           using infusion nurse and patient measured physical, quality of life (QOL), respiratory,\n           laboratory, and disability assessments in patients with Primary Immunodeficiency\n           Disease (PIDD).\n\n      Secondary:\n\n        -  Change in Intravenous/Subcutaneous Immunoglobulin (IVIg/SCIg) dose effects measured\n           outcomes.\n\n        -  Change in IVIg/SCIg dose timing effects measured outcomes.\n\n        -  Change in patient status is reflected in measured outcomes.\n\n        -  Assess the value to physicians from collected outcomes data.\n\n        -  Identify types of patients by response to IVIg/SCIg therapies (well maintained,\n           problematic, etc.).\n\n        -  Change in response rate as measured by outcomes to IVIg/SCIg therapies by disease\n           state, co-morbidities, and demographics."
        }, 
        "brief_title": "Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Immune Deficiency Disorder", 
        "condition_browse": {
            "mesh_term": "Immunologic Deficiency Syndromes"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, observational evaluation of immunoglobulin (Ig) therapy in consenting\n      PIDD adult and assenting pediatric subjects who receive infusion services from AxelaCare\n      Health Solutions, LLC.  Subjects meeting all inclusion criteria who have provided informed\n      consent/assent for trial participation will have validated, physician-prescribed,\n      standard-of-care outcome measures, and Ig administration information recorded during normal\n      home infusion visits.  There will also be standard-of-care questions captured within some\n      outcome measures recorded during normal home infusion visits that may be at a frequency\n      and/or combination which may not be considered routine clinical care by some physicians who\n      treat for this medical condition.  Collected data will be de-identified and aggregated into\n      cohorts of like diagnosis for trend analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of any form of Primary Immunodeficiency Disease\n\n          -  Age at enrollment \u2265 7\n\n          -  Sign informed consent/assented to participation\n\n          -  Ability to read and write English\n\n          -  Understanding of study procedures and ability to comply with study procedures for the\n             entire length of the study\n\n          -  Receiving Ig under the discretion of the patient's treating physician in accordance\n             with standard treatment practices\n\n          -  Have been on or is between doses of Ig under the discretion of the patient's treating\n             physician in accordance with standard treatment practices\n\n          -  Being considered to be prescribed Ig under the discretion of the patient's treating\n             physician in accordance with standard treatment practices\n\n          -  Determined to be eligible for infusion services by AxelaCare Health Solutions, LLC.\n             in collaboration with the patient's prescribing physician\n\n        Exclusion Criteria:\n\n          -  Children (age \u2264 6 years)\n\n          -  Prisoners, and other wards of the state\n\n          -  Determined to have non-competency of data collection requirements (physical\n             assessments and use of an iPAD\u2122) by the study participant's caregiver"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "7 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Any patient who is aged 7 years or greater at time of enrollment; who is on Ig therapy,\n        have been on or is between doses of Ig therapy, or is being considered to be prescribed Ig\n        therapy; provides informed consent for participation; and who has been determined to be\n        eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration with\n        the patient's prescribing physician. Subjects will be recruited from the practices of\n        participating physicians."
            }
        }, 
        "enrollment": {
            "#text": "1500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01883921", 
            "org_study_id": "AHS1-13-002"
        }, 
        "intervention": {
            "arm_group_label": "Immunoglobulin Therapy", 
            "intervention_name": "Immunoglobulin Therapy", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gamma-Globulins", 
                "Immunoglobulins", 
                "Antibodies", 
                "Immunoglobulins, Intravenous"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary Immunodeficiency", 
            "Immunodeficiencies", 
            "Primary Immunodeficiency Diseases", 
            "PIDD", 
            "CVID", 
            "PI", 
            "Common Variable Immunodeficiency", 
            "Hypogammaglobulinemia", 
            "Acquired Hypogammaglobulinemia", 
            "Immunology", 
            "Autoimmune Deficiency", 
            "Intravenous Immunoglobulin", 
            "Subcutaneous Immunoglobulin", 
            "IVIg", 
            "SCIg", 
            "Immune Globulin", 
            "Outcomes Research"
        ], 
        "lastchanged_date": "June 20, 2013", 
        "location": [
            {
                "contact": {
                    "email": "twalton@axelacare.com", 
                    "last_name": "Timothy Walton, MHS, CCRP", 
                    "phone": "877-342-9352"
                }, 
                "contact_backup": {
                    "email": "cturk@axelacare.com", 
                    "last_name": "Callie Turk, RN, MSN", 
                    "phone": "877-342-9352"
                }, 
                "facility": {
                    "address": {
                        "city": "Lenexa", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66219"
                    }, 
                    "name": "AxelaCare Health Solutions, LLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data in Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)", 
        "overall_contact": {
            "email": "twalton@axelacare.com", 
            "last_name": "Timothy Walton, MHS, CCRP", 
            "phone": "877-342-9352"
        }, 
        "overall_contact_backup": {
            "email": "cturk@axelacare.com", 
            "last_name": "Callie Turk, RN, MSN", 
            "phone": "877-342-9352"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "H James Wedner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Analysis of collected data captured in CareExchange\u2122 -ability to show and track changes in outcome data in PIDD patients.", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01883921"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Physician feedback will demonstrate if having real-time access to patient data captured during a home infusion will assist in the management of the patient's disease.", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Response rate for those receiving IVIg/SCIg therapies.", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Exhibit differences in response rate of IVIg/SCIg therapies across disease states and demographics", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }, 
            {
                "measure": "Measure variables within patients who receive IVIg/SCIg therapies", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 Years"
            }
        ], 
        "source": "AxelaCare Health Solutions, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AxelaCare Health Solutions, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}